- The stock price of Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) increased by over 20% pre-market today. This is why it happened.
The stock price of Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) – a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use – increased by over 20% pre-market today. Investors are responding positively to Sonoma Pharmaceuticals and its partner, the MicroSafe Group, announcing that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn Disinfectant and Sanitizer, which is manufactured by Sonoma for its partner MicroSafe using Sonoma’s patented Microcyn Technology.
Following the original approval by the TGA and entry into The Australian Register Of Therapeutic Goods for use against SARS-CoV-2 (COVID 19) in mid-2020, the TGA has now approved extended claims for the hard-surface disinfectant Nanocyn with a 15 second kill time against common viruses, including SARS-CoV-2, Norovirus (Gastro), and influenza, and a 30-second kill contact time against common bacteria like Staphylococcus aureus (MRSA), E. coli, Pseudomonas aeruginosa, fungi, and mold – including Candida Albicans.
In addition, Nanocyn had been previously certified by major aviation manufacturers. And the product can disinfect aircraft without damaging sensitive materials. It is also the only TGA registered hospital grade disinfectant of its kind to be certified by Good Environmental Choice Australia (GECA).
KEY QUOTE:
“Nanocyn is a game-changer for any hospital, aged care or health care facility, transportation-provider, business, school, tourism or hospitality venue wanting to ensure their premises are COVID-safe, not just from a pandemic point of view, but also the comfort that comes with using a non-toxic disinfectant that does not leave any harmful residues behind.”
— MicroSafe Group CEO Safa Qadumi
“We could not be more excited about making our safe and effective Microcyn Technology available to valued partners such as MicroSafe. We are continuously seeking to add to our network of international distributors to increase the reach of Sonoma products worldwide.”
— Bruce Thornton, Chief Operating Officer of Sonoma Pharmaceuticals
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
